Supplementary - Tocilizumab for polyarteritis nodosa
收藏NIAID Data Ecosystem2026-05-02 收录
官方服务：
资源简介：
Tocilizumab for polyarteritis nodosa. Supplementary data.
应用场景：
创建时间：
2025-01-20
相关数据集
Supplementary Material for: Predictors for 2-Year Functional and Morphological Outcomes of a Treat-and-Extend Regimen with Ranibizumab in Patients with Diabetic Macular Edema
Purpose: The purpose of the study was to investigate longer term functional and morphological outcomes and their predictors in diabetic macular edema (DME) following a treat-and-extend r
DataCite Commons2021-03-19 更新60
Supplementary Material for: Real-world outcomes of ranibizumab treatment in French patients with visual impairment due to Macular Edema secondary to Retinal Vein Occlusion: 24-month results from the BOREAL-RVO study.
Introduction Information about real-world ranibizumab use is needed to optimize treatment of macular edema secondary to retinal vein occlusion (RVO). The BOREAL-RVO study assessed treatment use, effec
DataCite Commons2023-07-22 更新40
Methodological quality of RCTs evaluating ranibizumab for indirect comparison.
AE: Adverse effects.*It was outstanding that in the 0.5 mg group 10.2% of patients discontinued because of adverse effects, in the 0.3 mg quarterly group 3.3% and in the 0.3 mg monthly group 4.3%, res
Figshare2015-12-02 更新20
Rationale and design of the “Tocilizumab in patients with moderate to severe COVID-19: an open-label multicentre randomized controlled” trial (TOCIBRAS)
ABSTRACT Introduction: Pro-inflammatory markers play a significant role in the disease severity of patients with COVID-19. Thus, anti-inflammatory therapies are attractive agents for potentially com
NIAID Data Ecosystem50
Supplementary - Tocilizumab for polyarteritis nodosa
Tocilizumab for polyarteritis nodosa. Supplementary data.
Mendeley Data30
